Stock comparison
IDEXX Laboratories
IRadimed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
IRMD
IRadimed
Market cap
$1.18B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | IRMD | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 68B | IDXX |
| Benjamin Graham | 80A | 89A | IRMD |
| Philip Fisher | 75B | 92A | IRMD |
| Peter Lynch | 71B | 76B | IRMD |
| Joel Greenblatt | 83C | 65C | IDXX |
| Charlie Munger | 87A | 78B | IDXX |
| Terry Smith | 84A | 75B | IDXX |
Side-by-side metrics
| Metric | IDXX | IRMD |
|---|---|---|
| Market cap | $44.12B | $1.18B |
| P/E (TTM) | 39.0x | 50.4x |
| EV/EBIT | 31.6x | 43.4x |
| ROIC (TTM) | 40.66% | 21.38% |
| Gross margin | 62.05% | 76.84% |
| Net margin | 24.63% | 27.36% |
| Revenue CAGR 5y | 7.56% | 18.99% |
| EPS CAGR 5y | 10.79% | 23.53% |
| Debt / Equity | 0.7x | - |
| Dividend yield | 0.0% | 1.33% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $1.18B+97%
- ROIC (TTM)40.66%vs 21.38%+47%
- EV/EBIT31.6xvs 43.4x+27%
- P/E (TTM)39.0xvs 50.4x+23%
IRMD leads on
- Debt / Equity-vs 0.7x+100%
- Dividend yield1.33%vs 0.0%+100%
- Revenue CAGR 5y18.99%vs 7.56%+60%
- EPS CAGR 5y23.53%vs 10.79%+54%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.